CONFERENCE SERIES: Technologies & Tools for Life Sciences
Recorded at: XGen Congress
Digital Course: Exploring the Epigenetic Toolbox
About this Product:
Discovering, understanding, and interpreting the role of epigenetic modifications have progressed rapidly over the past few years due to the advancement of molecular tools. The complexity of toolbox options mirrors the effects of epigenetics’ multilayered regulatory mechanisms. This digital course is designed to explore the tools and solutions available to enable your specific epigenetic research.
About this Product:
Over 103 Slides
Individual Copy: $345
Site License: $1380
Agenda At A Glance:
Utilizing ChIP-Chip and ChIP-qPCR-Based Technologies for Epigenetic Analysis
Jeff Falk, Ph.D., Director, Technology Applications, AVIVA Systems Biology
Biography: Dr. Jeffrey Falk is Director of Technology & Business Applications at Aviva Systems Biology in San Diego and has extensive expertise in the development and application of novel profiling and sequencing technologies. He was instrumental in the development and application of Aviva’s ChIP-Seq and ChIP-Chip (ChIP-DSL) technologies for identifying genome-wide epigenetic modification and transcription factor/promoter interactions and application of these technologies to biomarker, target, and drug discovery. Dr. Falk is also responsible for managing target selection and product development activities associated with Aviva’s high throughput antibody production and protein expression capabilities. Previously he served at DNA Microarray Inc, as Assistant Director of Molecular Biology & Genomics at Chugai Biopharmaceuticals , and as a Senior Scientist at Signal Pharmaceuticals. Dr. Falk received his PhD in Molecular Biology from Purdue University, and completed his Postdoctoral training in Dr. J. Gregor Sutcliffe's laboratory at the Scripps Research Institute.
Abscription and Other Sensitive Bisulfite-Free Methods to Measure DNA Methylation: Application to Diagnostics
Michelle M. Hanna, Ph.D., CEO and Scientific Director, Ribomed
Biography: Dr. Michelle Hanna, the founder and CEO of RiboMed Biotechnologies, received her Ph.D. in Chemistry from the University of California, Davis in 1983 and did her postdoctoral work in Biochemistry and Molecular Genetics as an American Cancer Society Postdoctoral Fellow at the University of California, Berkeley. She was an Assistant Professor of Biological Chemistry at UC Irvine College of Medicine where she received young investigator awards from the American Cancer Society and the Beckman Foundation. Dr. Hanna was a tenured Associate Professor of Chemistry and Biochemistry at the University of Oklahoma until August 1999, when she founded RiboMed Biotechnologies. Over the past 23 years, Dr. Hanna has been awarded over $10 million in grants and contracts from the ACS, the National Cancer Institute (NCI)/National Institutes of Health (NIH), the National Science Foundation (NSF), the National Institute of Allergies and Infectious Diseases (NIAID)/NIH, the Defense Advanced Research Projects Agency (DARPA), and the Homeland Security Advanced Projects Agency (HSARPA).
ChIP, Sequencing, and Everything In Between
Brian Egan, Ph.D., Product Manager, Active Motif, Inc.
Biography: Dr. Brian Egan received his Ph.D. in Biochemistry from Vanderbilt University, after which he became a postdoctoral fellow at the Salk Institute in San Diego to pursue HIV research. Later he acted as the program director in ChIP services at Genpathway, Inc., and he is currently the product manager of epigenetic services at Active Motif, Inc. in Carlsbad, CA.
About the Conference:
X-Gen Congress and Expo is the event for the genomics revolution, promoting the cross-fertilization of established and emerging technologies, along with exciting applications for next-generation sequencing. This year’s programming addresses the technological advances enabling faster and cheaper DNA/RNA mapping, creating genomic comparisons and accelerating genomic discoveries. It will also showcase next-generation sequencing platforms creating sequence reads of DNA fragments for genome variation studies, RNA for transcriptome studies, DNA-protein interactions for epigenetic studies, and chromosomal DNA of large genome nucleotide variations for copy number studies.